Flawed Medical Protocol That Mainstreamed Child Sex Changes Was Funded by Puberty Blocker Company

By Hudson Crozier

What is the Dutch Protocol? It’s the standard medical protocol for when to give treatments to gender-dysphoric children, based on a few Dutch studies. First referenced in 2006, it allows puberty blockers at age 12, hormones at 16, and surgery at 18. It’s used around the world and helped make child sex changes mainstream.

The funding: The protocol was funded by Ferring Pharmaceuticals, which manufactured triptorelin, the puberty-blocking drug used in the research. The Dutch Protocol effectively helped to mainstream the company's product.

It’s also deeply flawed: Some of the Dutch studies that formed the protocol had methodological flaws and were designed to exclude children who experienced negative effects from transgender treatments. They also claimed without proof that the treatments were the sole cause of improvements in mental health when patients were also receiving traditional therapy. One study had a follow-up period of only 18 months.

The real effects: The Food and Drug Administration has warned that puberty blockers can cause vision loss and swelling in the brain. A “trans affirming” doctor recently admitted that the drugs cause a loss of sexual function. The Dutch studies, however, ignored physical effects such as these by focusing on mental outcomes. One participant in the experiments even died due to complications from a gender surgery.

The bottom line: It’s not just recent medical data supporting child sex changes that have come under scrutiny. The flaws and corruption of transgender science can be traced all the way back to its disturbing origins, as Upward News has covered.

Join the conversation

or to participate.